This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-06 and is reviewed periodically as new material appears.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
== Uses == Benzophenone can be used as a photo initiator in ultraviolet (UV)-curing applications such as inks, imaging, and clear coatings in the printing industry. Benzophenone prevents UV light from damaging scents and colors in products such as perfumes and soaps. Benzophenone can also be added to plastic packaging as a UV blocker to prevent photo-degradation of the packaging polymers or its contents. Its use allows manufacturers to package the product in clear glass or plastic (such as a PETE water bottle). Without it, opaque or dark packaging would be required. In biological applications, benzophenones have been used extensively as photophysical probes to identify and map peptide–protein interactions. Benzophenone is used as an additive in flavorings or perfumes for "sweet-woody-geranium-like notes".
This reasoning was conditioned by Russia's historical experiences, given the frequency with which the country had been invaded over the preceding 150 years. The Second World War experience was particularly dramatic for the Russians: the Soviet Union suffered unprecedented devastation as a result of the Nazi onslaught, and over 20 million Soviet citizens died during the war; tens of thousands of Soviet cities, towns, and villages were leveled; and 30,100 Soviet factories were destroyed. In order to prevent a similar assault in the future, Stalin was determined to use the Red Army to gain control of Poland, to dominate the Balkans and to destroy utterly Germany's capacity to engage in another war. The problem was that Stalin's strategy risked confrontation with the equally powerful United States, who viewed Stalin's actions as a flagrant violation of the Yalta agreement. At the end of the war in Europe, in May 1945, the Soviets insisted on occupying the Danish island of Bornholm, due to its strategic position at the entrance to the Baltic. When the local German commander insisted on surrendering to the Western Allies, as did German forces in the rest of Denmark, the Soviets bombed the island, causing heavy casualties and damage among a civilian population which was only lightly touched throughout the war, and then invaded the island and occupied it until mid-1946—all of which can be considered as initial moves in the Cold War.
=== Sézary cells === Sézary cells are bigger than Lutzner cells, and have an overabundance of cellular folds in the membrane. They are also considered over pigmented and have large cerebriform nuclei with a small cytoplasm. Sézary cells are found in both mycosis fungoides and Sézary disease.
=== Sleeping sickness treatment === The drug was registered for the treatment of gambiense sleeping sickness on 28 November 1990. However, in 1995 Aventis (now Sanofi-Aventis) stopped producing the drug, whose main market was African countries, because it did not make a profit. In 2001, Aventis and the WHO formed a five-year partnership, during which more than 320,000 vials of pentamidine, over 420,000 vials of melarsoprol, and over 200,000 bottles of eflornithine were produced by Aventis, to be given to the WHO and distributed by the association Médecins sans Frontières (also known as Doctors Without Borders) in countries where sleeping sickness is endemic. According to Médecins sans Frontières, this only happened after "years of international pressure," and coinciding with the period when media attention was generated because of the launch of another eflornithine-based product (Vaniqa, for the prevention of facial-hair in women), while its life-saving formulation (for sleeping sickness) was not being produced.
Sources: en.wikipedia.org
It was inspired by the documentary Bond Girls Are Forever, which she produced with Planetgrande, featuring d'Abo and other Bond girls, including Ursula Andress, Honor Blackman, Jill St. John, Maud Adams, Lois Chiles, Judi Dench, Rosamund Pike, Eva Green, Halle Berry, and Carey Lowell. The documentary appeared on the American AMC network in 2002, timed to coincide with the theatrical release of Die Another Day. It was later included as a gift with the purchase of Die Another Day on DVD by some retailers. In 2006, a new version of the documentary, updated to include interviews with cast from Casino Royale (2006) was again aired on the AMC network and later released as a bonus feature on the March 2007 Blu-ray disc and DVD release of Casino Royale. In 2004 she wrote and, with Cabin Creek Films, co-produced the documentary film Bearing Witness, about five female war reporters featuring Marie Colvin and Janine di Giovanni, which Barbara Kopple and Marijana Wotton directed for A&E. The feature documentary premiered at the Tribeca Film Festival. In 2007, she had surgery for a brain hemorrhage; after recovering, she was inspired to meet other people who had similar experiences. She then worked on and produced a 2011 documentary on the topic titled Rupture: A Matter of Life and Death. In 2009, she had a supporting role in the British period fantasy-thriller Dorian Gray. She appeared in the 2014 Indian film Tigers directed by Danis Tanovic, and made her return to the horror genre in 2025 with the British film The Baby in the Basket. D'Abo is signed to Models 1.
== Retail products == In 2016, the company began offering a canned version of the Draft Latte, a cold-pressed espresso and frothed milk latte which was available on tap in stores. Draft Lattes were initially available in four flavors. The cans for the latte were designed by CEO Todd Carmichael and produced by Crown Holdings. The can employed a valve mechanism at the base for injection of nitrous oxide. Manufacturing of the cans moved from Pennsylvania to a new facility in Norton Shores, Michigan in 2016. A Nitro cold brew was also in the works around 2015. Other products include Different Drum, a coffee-infused rum, produced at a micro-distillery located in its Fishtown, Philadelphia cafe, and a line of La Colombe single-origin and blended roasted coffees, which are available for purchase in retail stores or via the company's website. The company also produces retail cold brew in larger 42oz bottles. In 2020, the company announced a can of instant coffee with new self-heating technology.
=== Quantification in disease === Elevation of serum, plasma, or tissue SP and/or its receptor (NK1R) has been associated with many diseases: sickle cell crisis; inflammatory bowel disease; major depression and related disorders; fibromyalgia; rheumatological; and infections such as HIV/AIDS and respiratory syncytial virus, as well as in cancer. When assayed in the human, the observed variability of the SP concentrations are large, and in some cases the assay methodology is questionable. SP concentrations cannot yet be used to diagnose disease clinically or gauge disease severity. It is not yet known whether changes in concentration of SP or density of its receptors is the cause of any given disease, or an effect.
There have been few incidents of doping in football, mainly because of little unannounced testing relative to the high amount of professionals. There is also a lack of further investigation (e.g. Tony Schumacher revelations and the still unknown footballers of Eufemiano Fuentes), preservation of samples, and consequences. In 2014, the biological passport was introduced in the 2014 FIFA World Cup; blood and urine samples from all players before the competition and from two players per team and per match are analysed by the Swiss Laboratory for Doping Analyses.
On September 25, Xi and Peng returned to the White House with Donald and Melania Trump. They then attended a tea ceremony in the Red Room. Trump said US farmers "are going to be very happy" with the talks, adding "A lot of very positive things happened, but America is very happy about this visit and I’m sure China is very happy also". He said "We’ve had a tremendous visit from two spectacular people" and "We’ve really enjoyed it and I think we’ve been tremendous strides. We’ve made great strides, very positive for both countries." During this tea ceremony, Xi said that he and Trump "are like two people who are charting the course for the great ship of China-U.S. relations." Xi also confirmed that two leaders will to see each other later this year in twice, including APEC summit in Shenzhen and G20 Summit in Miami. Later, Xi and Trump visited the National Archives, and viewed the Declaration of Independence, the Constitution and the Bill of Rights. According to the NPR, a table that included a temporary display showcasing a brick from the Great Wall of China and an 19th century scroll sent by a Qing emperor was removed because the display also planned to show the Treaty of San Francisco, which China considers as illegitimate because it was not a signatory. Other documents, including Six Assurances and the Three Communiqués, were also discussed for display, but ultimately not included.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.